- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
The European Medicines Agency (EMA) has started a rolling review of Sinovac's COVID-19 Vaccine (Vero Cell) Inactivated based on preliminary results from non-clinical and clinical studies. EMA will decide if the benefits of this vaccine outweigh the risks, and the review will continue until there is sufficient evidence to apply for marketing authorisation. EMA will also assess the effectiveness, safety and quality of this vaccine and will later confirm when the marketing authorisation application for the vaccine has been submitted.
Additional data provided by
English
Japanese
